| Julie A Smith, FNP | |
|
1836 South Ave, La Crosse, WI 54601-5429 | |
| (608) 782-7300 | |
| Not Available |
| Full Name | Julie A Smith |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 22 Years |
| Location | 1836 South Ave, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063493674 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 2120 (Wisconsin) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 2120 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Gundersen Lutheran Medical Center | La crosse, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gundersen Lutheran Medical Center Inc | 2163331414 | 800 |
News Archive
Cerus Corporation announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets.
A study led by researchers at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health has identified a constellation of metabolites related to myalgic encephalomyelitis/chronic fatigue syndrome.
Colistin is used as the "last-resort antibiotic" for dreaded multidrug-resistant pathogens, especially in hospitals. However, gut bacteria that have become insensitive to colistin now exist - owing to the mobile resistance gene mcr-1. In early 2016, bacteria carrying this resistance gene were detected in Germany for the first time.
Cyberonics, Inc., a global leader in epilepsy management, today announced results for the fourth quarter and fiscal year ended April 29, 2011.
› Verified 3 days ago
| Entity Name | Gundersen Lutheran Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376593442 PECOS PAC ID: 2163331414 Enrollment ID: O20130619000254 |
News Archive
Cerus Corporation announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets.
A study led by researchers at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health has identified a constellation of metabolites related to myalgic encephalomyelitis/chronic fatigue syndrome.
Colistin is used as the "last-resort antibiotic" for dreaded multidrug-resistant pathogens, especially in hospitals. However, gut bacteria that have become insensitive to colistin now exist - owing to the mobile resistance gene mcr-1. In early 2016, bacteria carrying this resistance gene were detected in Germany for the first time.
Cyberonics, Inc., a global leader in epilepsy management, today announced results for the fourth quarter and fiscal year ended April 29, 2011.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie A Smith, FNP 1836 South Ave, La Crosse, WI 54601-5429 Ph: () - | Julie A Smith, FNP 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 |
News Archive
Cerus Corporation announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets.
A study led by researchers at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health has identified a constellation of metabolites related to myalgic encephalomyelitis/chronic fatigue syndrome.
Colistin is used as the "last-resort antibiotic" for dreaded multidrug-resistant pathogens, especially in hospitals. However, gut bacteria that have become insensitive to colistin now exist - owing to the mobile resistance gene mcr-1. In early 2016, bacteria carrying this resistance gene were detected in Germany for the first time.
Cyberonics, Inc., a global leader in epilepsy management, today announced results for the fourth quarter and fiscal year ended April 29, 2011.
› Verified 3 days ago
Stacie Strong, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2500 State Rd # 33, La Crosse, WI 54601 Phone: 608-775-5858 | |
Julie Sonsalla, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Naomi Muthoni Ruiru, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Catherine A Ziegler, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 800 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940 | |
Lisa Malmo, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 700 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940 | |
Tneshia Janeen Sweat, NNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Kathleen Marie Grangaard, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 700 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940 |